Novo Nordisk A/S

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
>
Registration as it was on 14 Mar 2025
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

900,000€ - 999,999€

Financial year: Jan 2024 - Dec 2024

Lobbyists (Full time equivalent)

5.2 Fte (19)

Lobbyists with EP accreditation

4

High-level Commission meetings

10

Lobbying Costs over the years

  • Info

    Novo Nordisk A/S

    EU Transparency Register

    29570313329-11 First registered on 13 Mar 2010

    Goals / Remit

    Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to serious chronic diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure the diseases we treat. We employ more than 60,000 people in 80 countries, and market our products in 170 countries. In 2023, we served more than 40 million patients worldwide. In 2023, we served more than 6 million patients in the EU. More than 30,000 of our employees are based in the EU. Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line).The controlling stake in Novo Nordisk is owned by the Novo Nordisk Foundation. This is a non-profit institution, whose formal purpose is to provide a stable basis for its companies’ operations and to make contributions to scientific, humanitarian and social progress.

    Main EU files targeted

    EU pharmaceutical-related policy, as well as broader health, environmental and business-related policy.

    Address

    Head Office
    Novo Nordisk A/SNovo Allé, 1
    Bagsværd 2880
    DENMARK
    EU Office
    Square de Meeûs 35
    Brussels 1000
    BELGIUM

    Website

    http://www.novonordisk.com

  • People

    Total lobbyists declared

    19

    Employment timeLobbyists
    75%3
    50%3
    25%1
    10%12

    Lobbyists (Full time equivalent)

    5.2

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    4 accreditations were / are live (in bold) for the selected state of 16 Mar 2025

    Name Start date End Date
    Alexander Von Wildenrath LØVGREEN 26 Nov 2024 26 Nov 2025
    Cecilie Fenger Michaelsen 25 Nov 2024 25 Nov 2025
    Marie Hjortdal Nielsen 08 Apr 2024 08 Apr 2026
    Helen Oberg 08 Apr 2024 08 Apr 2026
    Matthew Thomas Vincent CLAY 27 Oct 2023 04 Oct 2024
    Alexander Von Wildenrath LØVGREEN 08 Apr 2024 22 Nov 2024
    Ms Helen Oberg 12 Apr 2023 26 Apr 2024
    Mr Christian JUUL NYHUS 16 Feb 2023 16 Feb 2024
    Mr Alexander VON WILDENRATH LØVGREEN 16 Feb 2023 16 Feb 2024
    Mr Matthew CLAY 07 Jun 2022 07 Jun 2023
    Mr Vincent CLAY 07 Jun 2022 27 Jun 2022
    Jeppe Torp VESTENTOFT 03 Dec 2019 01 Aug 2020
    Ms Victoria Breck 30 Nov 2019 28 Nov 2020
    Ms Ane Sofie Böhm Nielsen 23 Sep 2014 19 Sep 2015
    Mr Troels Anders RYE-ANDERSEN 08 Aug 2014 06 Aug 2015
    Mr Morten Frank Pedersen 19 Sep 2013 18 Sep 2014
    Ms Engelbertha Maria Rouweler 17 Sep 2013 14 Mar 2014
    Mr Neil David Causey 17 Sep 2013 14 Sep 2014
    Mr Troels Anders RYE-ANDERSEN 07 Jun 2013 06 Jun 2014
    Mr Troels Anders RYE-ANDERSEN 16 Jan 2012 08 Feb 2013

    Complementary Information

    A range of Novo Nordisk colleagues contribute their expertise to activities covered by the Register, directly or through trade associations. We have used 10% relevant working time as the threshold for including colleagues in our FTE calculations.

    We have updated our annual declaration for 2024 using EFPIA membership costs from 2023. EFPIA are preparing their Transparency Register-related costs ahead of their annual declaration, which is due later this year, at which point we will update our entry. Novo Nordisk’s overall contribution to EFPIA is comparable in 2024 to 2023.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Novo Nordisk is a member of:

    - EFPIA
    - The Danish Chamber of Commerce
    - The Confederation of Danish Industries
    - Science|Business
    - EUCOPE

    Member organisations

    n/a

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2024 - Dec 2024

    Lobbying costs for closed financial year

    900,000€ - 999,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    acumen public affairs 100,000€ - 199,999€
    copenhagen economics 25,000€ - 49,999€
    fipra international srl 50,000€ - 99,999€
    rud pedersen public affairs brussels 10,000€ - 24,999€
    trade council, ministry of foreign affairs, denmark. 10,000€ - 24,999€

    Intermediaries for current year

    Name
    acumen public affairs
    trade council, ministry of foreign affairs, denmark

    Closed year Costs

    900,000€ - 999,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    The LinkedIn account of our CEO, Lars Fruergaard Jørgensen, may sometimes include content relevant to activities covered by the Register: https://www.linkedin.com/in/larsfruergaard/

    Other executive communications sometimes also reference EU policy.

    Other activities

    None declared

  • Meetings

    Meetings

    10 meetings found. Download meetings

    The list below covers meetings with Commissioners/Cabinet members/Directors-general (high-level) Commission meetings published December 2014 to December 2024, and the meetings of Commissioners/Cabinet members/Directors-general and officials holding "management functions" in the Commission published since 1 January 2025. Other lobby meetings with lower-level staff may well have taken place, but the Commission doesn't proactively publish information about these meetings. All information below comes from the Commission and not from the registrant.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

Download this datacard